AstraZeneca And BenevolentAI Advance AI Partnership With Second Novel Target

Focus On Biology Paying Off

 
• By Andrew McConaghie

AstraZeneca and BenevolentAI claim their partnership is augmenting and accelerating validation of new drug targets.

AstraZeneca Cambridge
AstraZeneca's new Discovery Centre (DISC) In Cambridge, UK. • Source: Alamy

More from Respiratory

More from Therapy Areas